Goal Directed Therapy for Patients Undergoing Major Vascular Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr. Duane Funk, University of Manitoba
ClinicalTrials.gov Identifier:
NCT01681251
First received: May 18, 2011
Last updated: November 7, 2013
Last verified: November 2013
  Purpose

The management and delivery of intravenous fluids during surgical operations is one of the important duties for anesthesiologists.

The goal of this study was to determine if goal directed fluid therapy, titrated using the FloTrac monitor's measurement of stroke volume variation results in a decrease in the length of stay of patients undergoing open abdominal aneurysm repair.


Condition Intervention Phase
Abdominal Aortic Aneurysm Uncomplicated
Other: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
Other: Fluid titrated at the discretion of the attending anesthesiologist
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Goal Directed Therapy for Patients Undergoing Major Vascular Surgery

Resource links provided by NLM:


Further study details as provided by University of Manitoba:

Primary Outcome Measures:
  • Length of Stay [ Time Frame: Up to 180 days. ] [ Designated as safety issue: No ]
    Patients will be assessed for fitness for hospital discharge. This will be used to calculate the length of stay.


Secondary Outcome Measures:
  • Total Crystalloid Use [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • Total Colloid Use [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • Requirement for red blood cell transfusion [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Fluid balance [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Urine output [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Serum creatinine [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Postoperative complications [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Including: myocardial infarction, sepsis, pneumonia, renal failure, bleeding, ICU admission.

  • Neutrophil gelatinase associated lipocalnin (NGAL) levels [ Time Frame: Pre-op, immediately post op, 6 hours post-op and 24 hours post-op ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: August 2010
Study Completion Date: October 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intervention
Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
Other: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%

Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.

Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV.

Active Comparator: Control
Fluid titrated at the discretion of the attending anesthesiologist.
Other: Fluid titrated at the discretion of the attending anesthesiologist
In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • American Society of Anesthesiologists physical class I-III patients over the age of 18 years
  • Presenting for elective open repair of abdominal aortic aneurysms.

Exclusion Criteria:

  • Weight >120kg
  • Known or suspected valvular aortic insufficiency
  • Renal Dysfunction (serum creatinine >150 μmol/l)
  • Pre-existing bowel dysfunction
  • Active congestive heart failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01681251

Locations
Canada, Manitoba
University of Manitoba
Winnipeg, Manitoba, Canada, R3T2N2
Sponsors and Collaborators
University of Manitoba
Investigators
Principal Investigator: Duane J Funk, MD University of Manitoba
  More Information

No publications provided

Responsible Party: Dr. Duane Funk, Assistant Professor, University of Manitoba
ClinicalTrials.gov Identifier: NCT01681251     History of Changes
Other Study ID Numbers: B2009:135
Study First Received: May 18, 2011
Last Updated: November 7, 2013
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Aneurysm
Aortic Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 22, 2014